SCHEMBL6502976

SCHEMBL6502976

CON(C)C(=O)CCN1CCCCC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.50
MAPT P10636 6/20 0.50
POLB P06746 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.48
KMT2A Q03164 5/20 0.44
LMNA P02545 4/20 0.44
HTT P42858 3/20 0.44
MEN1 O00255 1/20 0.44
TP53 P04637 3/20 0.43
TSHR P16473 2/20 0.43
HPGD P15428 1/20 0.43
CYP1A2 P05177 1/20 0.43
MAPK1 P28482 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
USP2 O75604 1/20 0.42
HSD17B10 Q99714 1/20 0.42
ALOX15 P16050 1/20 0.42
SIGMAR1 Q99720 2/20 0.40
GLA P06280 1/20 0.40
ATM Q13315 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27318777 0.84 SIGMAR1 (0.46) ALDH1A1MAPTPOLBL3MBTL1KMT2A
SCHEMBL6493750 0.81 GAA (0.44) ALDH1A1KMT2AHTTMEN1SMN1; SMN2
SCHEMBL27976380 0.79 ALDH1A1 (0.54) ALDH1A1MAPTPOLBL3MBTL1KMT2A
SCHEMBL4895254 0.76 PAOX (0.49) ALDH1A1L3MBTL1LMNATP53TSHR
SCHEMBL3442885 0.76 PDCD1 (0.39) KMT2AMEN1SMN1; SMN2
SCHEMBL3442886 0.76 PDCD1 (0.39) KMT2AMEN1SMN1; SMN2
SCHEMBL4002137 0.73 GLA (0.45) ALDH1A1LMNATP53TSHRSMN1; SMN2
SCHEMBL4019745 0.73 PHF8 (0.39) ALDH1A1KMT2ALMNAMEN1TSHR
SCHEMBL65134 0.73 SMN1; SMN2 (0.59) ALDH1A1MAPTPOLBL3MBTL1KMT2A
SCHEMBL10409891 0.73 SMN1; SMN2 (0.59) ALDH1A1MAPTPOLBL3MBTL1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6936606-B2 Cyanoamido-containing heterocyclic compounds useful as reversible inhibitors of cysteine proteases BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2005-08-30 US disclosed
EP-1434769-A2 COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2004-07-07 EP disclosed
US-20040063679-A1 Compounds useful as reversible inhibitors of cysteine proteases BOEHRINGER INGELHEIM PHARMACEUTICALS INC. 2004-04-01 US disclosed
WO-2003029200-A2 COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2003-04-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063679-A1 Compounds useful as reversible inhibitors of cysteine proteases CTSS, CTSK, CTSB ALDH1A1 2191/4885MAPT 4572/4885POLB 1919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.